: 561 
The inheritance probabilities per birth are as follows:

If both parents are carriers:
25% (1 in 4) children will have the disorder
50% (2 in 4) children will be carriers (but unaffected)
25% (1 in 4) children will be free of MSD - unaffected child that is not a carrier
If one parent is affected and one is free of MSD:
0% (0) children will have the disorder - only one parent is affected, other parent always gives normal gene
100% (4 in 4) children will be carriers (but unaffected)
If one parent is a carrier and the other is free of MSD:
50% (2 in 4) children will be carriers (but unaffected)
50% (2 in 4) children will be free of MSD - unaffected child that is not a carrier

Diagnosis
MSD may be diagnosed when deficiency of more than one sulfatase enzyme is identified in leukocytes or fibroblasts, or by molecular genetic testing which shows pathogenic variation in both alleles of the SUMF1 gene. Treatment
As there is no cure for MSD, treatment is restricted to management of symptoms. There is much research on MSD that is currently underway. MSD Action Foundation have initiated more than 15 research projects on MSD in the last 6 years. Many of these have a translational focus. It is hoped that clinical trials for MSD will happen in the not too distant future- Alan Finglas. [Ref 17. Finglas 2020]

See also
Linear porokeratosis
List of cutaneous conditions

References

[17] View from inside: When multiple sulfatase deficiency changes everything about how you live and becomes your life
Alan Finglas,
https://doi.org/10.1002/jimd.12305
== External links ==SavingDylan.com
In hemoglobin H disease, red blood cells containing hemoglobin H inclusions can be visualized on the blood smear using new methylene blue or brilliant cresyl blue stain.Hemoglobin analysis is important for the diagnosis of alpha-thalassemia as it determines the types and percentages of types of hemoglobin present. Several different methods of hemoglobin analysis exist, including hemoglobin electrophoresis, capillary electrophoresis and high-performance liquid chromatography.Molecular analysis of DNA sequences (DNA analysis) can be used for the confirmation of a diagnosis of alpha-thalassemia, particularly for the detection of alpha-thalassemia carriers (deletions or mutations in only one or two alpha-globin genes). Treatment
Treatment for alpha-thalassemia may include blood transfusions to maintain hemoglobin at a level that reduces symptoms of anemia. The decision to initiate transfusions depends on the clinical severity of the disease. Splenectomy is a possible treatment option to increase total hemoglobin levels in cases of worsening anemia due to an overactive or enlarged spleen, or when transfusion therapy is not possible. However, splenectomy is avoided when other options are available due to an increased risk of serious infections and thrombosis.Additionally, gallstones may be a problem that would require surgery. Secondary complications from febrile episode should be monitored, and most individuals live without any need for treatment. Additionally, stem cell transplantation should be considered as a treatment (and cure), which is best done in early age.